Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15725321 | 0.96 | HTR1A (0.37) | HTR1ACARM1PRMT6EPHX2 | |
| SCHEMBL26036150 | 0.88 | HTR1A (0.41) | HTR1ACARM1PRMT6 | |
| SCHEMBL15725323 | 0.88 | HTR1A (0.33) | HTR1ACARM1PRMT6 | |
| SCHEMBL15725325 | 0.88 | HTR1A (0.33) | HTR1ACARM1PRMT6 | |
| SCHEMBL18077324 | 0.87 | HTR1A (0.34) | HTR1ACARM1PRMT6 | |
| SCHEMBL4549774 | 0.84 | NAAA (0.37) | HTR1ACARM1PRMT6 | |
| SCHEMBL15725326 | 0.83 | HTR1A (0.35) | HTR1ACARM1PRMT6EPHX2 | |
| SCHEMBL15725324 | 0.83 | HTR1A (0.35) | HTR1ACARM1PRMT6EPHX2 | |
| SCHEMBL15727932 | 0.82 | HTR1A (0.36) | HTR1ACARM1PRMT6EPHX2 | |
| SCHEMBL10302569 | 0.80 | HTR1A (0.38) | HTR1ACARM1PRMT6EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180171231-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-9951274-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2018-04-24 | — | — | US | disclosed |
| US-20180030350-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2018-02-01 | — | — | US | disclosed |
| US-9580653-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2017-02-28 | — | — | US | disclosed |
| US-20170044438-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044437-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| US-20170037316-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-09 | — | — | US | disclosed |
| US-20160319194-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2016-11-03 | — | — | US | disclosed |
| US-9234136-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-20150322342-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2015-11-12 | — | — | US | disclosed |
| US-20150175884-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-20140138581-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044438-A1 | LIQUID-CRYSTALLINE MEDIUM | VIM, COL2A1, COL1A1 | HTR1A 463/4885CARM1 384/4885PRMT6 2938/4885 |
| US-20170037316-A1 | LIQUID-CRYSTALLINE MEDIUM | FES, NEFM, SOST | HTR1A 530/4885CARM1 3050/4885PRMT6 4275/4885 |
| US-20180030350-A1 | LIQUID-CRYSTALLINE MEDIUM | VIM, COL2A1, COL1A1 | HTR1A 463/4885CARM1 384/4885PRMT6 2938/4885 |
| US-20170044437-A1 | LIQUID-CRYSTALLINE MEDIUM | VIM, COL2A1, COL1A1 | HTR1A 463/4885CARM1 384/4885PRMT6 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.